Picard Medical

Picard Medical Net Margin

The Net Profit Margin of Picard Medical (PMI) as of Nov 12, 2026 is -546.56 %. In the previous year, Net Profit Margin was -479.50 % — a change of 13.98% (lower).

Net Margin

-546.56 %

YoY

13.98%

Last updated:

Net Profit Margin of Picard Medical is 2025 -546.56 % . Net Profit Margin of Picard Medical was 2024 -479.50 % . It decreases by 13.98% lower compared to the previous year.

Picard Medical's net margin stands at -546.6%, down from -271.5% several years earlier.

The Picard Medical Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2022
-271.53 USD
Jan 1, 2023
-308.72 USD
Jan 1, 2024
-479.50 USD
Jan 1, 2025
-546.56 USD
The Picard Medical Net Margin history
YEARNet MarginYoY
-546.56 %+13.98%
-479.50 %+55.32%
-308.72 %+13.70%
-271.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Picard Medical Stock analysis

What does Picard Medical do? Picard Medical Inc generates revenue through its wholly-owned subsidiary SynCardia Systems, LLC, which produces and sells the SynCardia TAH, the only FDA and Health Canada-approved implantable total artificial heart. The product consists of an implantable device, an external pneumatic driver, and drivelines connecting them, designed for biventricular heart replacement. Hospitals and cardiac care centers purchase these systems for patients with end-stage heart failure requiring temporary or permanent heart replacement. The company's revenue model relies on direct sales of the SynCardia TAH system to healthcare institutions specializing in advanced cardiac treatments. SynCardia Systems, LLC focuses on the medical technology segment within the health care equipment and supplies industry, targeting hospitals and medical facilities that perform complex cardiac procedures. The SynCardia TAH is marketed as a life-saving solution for patients with severe heart conditions, with no competing FDA-approved alternatives. The company's revenue stream is derived from the sale of the complete system, including the implant, driver, and drivelines, to healthcare providers who serve patients in critical cardiac care scenarios. The SynCardia TAH system is the sole product line of SynCardia Systems, LLC, with no other medical devices or services offered by the subsidiary. Picard Medical Inc's business model centers on the exclusive distribution of this FDA-approved artificial heart, which is used in both temporary and permanent heart replacement cases. The company's revenue is generated solely through the sale of the SynCardia TAH system to hospitals and cardiac care centers that specialize in treating end-stage heart failure patients. Picard Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Picard Medical stock

Net Profit Margin of Picard Medical is -546.56 % in 2025.

Net Profit Margin of Picard Medical changed from -479.50 % to -546.56 %, representing a 13.98% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Picard Medical since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Picard Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Picard Medical

All Key Metrics — Picard Medical